FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment. Follow-up FDG positron emission tomography (PET) scans were performed in a patient after cessation of treatment and in the other under treatment. Both FDG PET findings showed reduced FDG uptake in the bone marrow. A series of these FDG PET findings suggest the usefulness of FDG PET for the diagnosis and monitoring of chronic myeloid leukemia after treatment.
Nakajo
Masatoyo
M
Department of Radiology, Atsuchi Memorial Clinic PET Center, Kagoshima, Japan. toyo.nakajo@dolphin.ocn.ne.jp
Jinnouchi
Seishi
S
Inoue
Hirosaka
H
Otsuka
Maki
M
Matsumoto
Tadashi
T
Kukita
Toshimasa
T
Tanabe
Hiroaki
H
Tateno
Rie
R
Nakajo
Masayuki
M
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate